Merit Medical Systems, Inc. (MMSI) recently announced the U.S. commercial release of the basixSKY Inflation Device. The device is available as a standalone solution and in kits with Merit Medical's Angioplasty Packs, configured to offer complementing AccessPLUS, Honor, and PhD hemostasis valves. This month, Merit Medical received the FDA's 510(k) clearance for its Siege Vascular Plug. The company also announced the launch of its Bearing nsPVA Express Prefilled Syringe in the United States and Australia. The ...

Merit Medical Systems, Inc. (MMSI) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism led by solid first-quarter 2024 performance and its continued spend on research and development (R&D) are expected to contribute further. However, headwinds due to higher consolidation in the healthcare industry and forex volatility persist. Over the past year, this Zacks Rank #3 (Hold) stock has gained 1.4% compared with a 5.5% rise of the industry and 28.6% growth of ...

Group 1 - Merit Medical Systems, Inc. has announced the US commercial release of the basixSKY Inflation Device, expanding its portfolio of healthcare technology products [1][2] - The basixSKY is designed for ease of use, featuring a comfort-grip for one-handed preparation and minimizing rotational torque and handle revolutions to reach pressure [3] - The device is part of a comprehensive inflation device portfolio that includes both digital and analog solutions, as well as custom kit options [2][4] Group 2 - Endovascular interventions, such as balloon angioplasty and stent placement, are expected to reach 1.79 million procedures in the US in 2024, highlighting the demand for inflation devices [4] - Merit Medical, founded in 1987, specializes in the development, manufacture, and distribution of proprietary disposable medical devices across various medical fields, employing approximately 7,000 individuals globally [4]

SOUTH JORDAN, Utah, May 21, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced the US commercial release of the basixSKY Inflation Device. CONTACTS PR/Media Inquiries Sarah Comstock Merit Medical +1-801-432-2864 |sarah.comstock@merit.com INVESTOR INQUIRIES Mike Piccinino, CFA, IRC Westwicke - ICR +1-443-213-0509 |mike.piccinino@westwicke.com TRADEMARKS Unless noted otherwise, trademarks and registered trademarks used in this release ...

Core Points - Merit Medical Systems, Inc. announced the election of Silvia M. Perez as a director during its Annual Meeting of Shareholders held on May 15, 2024 [1] - Shareholders also re-elected Fred P. Lampropoulos and Stephen C. Evans as directors, all serving three-year terms [1] Group 1: Leadership Changes - Silvia Perez brings over two decades of experience in the healthcare industry, with a strong background in clinical, regulatory, operations, marketing, and business leadership [2] - Mr. Lampropoulos expressed confidence that Ms. Perez's expertise will provide valuable insights for the company's growth initiatives [2] - Ms. Perez has held various leadership roles at 3M Company since 1994, including President of the Commercial Solutions Division and Vice President of Acelity, Inc. [3] Group 2: Educational Background - Ms. Perez holds a pharmaceutical chemist degree from the University of the Republic in Uruguay and is an industrial pharmacist educated at the Federal University of Parana in Brazil [4] - She possesses Six Sigma Black Belt and Master Black Belt certifications, indicating a strong foundation in quality management and process improvement [4] Group 3: Company Overview - Merit Medical Systems, founded in 1987, specializes in the development, manufacture, and distribution of proprietary disposable medical devices for interventional, diagnostic, and therapeutic procedures [5] - The company serves hospitals worldwide with a sales force and clinical support team of over 700 individuals and employs approximately 7,000 people globally [5]

Core Points - Merit Medical Systems, Inc. announced the election of Silvia M. Perez as a director during its Annual Meeting of Shareholders on May 15, 2024 [1] - Shareholders also re-elected Fred P. Lampropoulos and Stephen C. Evans for three-year terms [1] - Mr. Lampropoulos expressed confidence that Ms. Perez's leadership experience will enhance the board's and management's perspective as the company pursues growth initiatives [2] - Ms. Perez has over two decades of experience in the healthcare industry, with a strong background in various leadership roles [2][3] - She has been with 3M Company since 1994, holding significant positions including President of Commercial Solutions Division [3] - Ms. Perez holds degrees in pharmaceutical chemistry and industrial pharmacy, along with Six Sigma Black Belt certifications [4] Company Overview - Merit Medical Systems, founded in 1987, specializes in the development, manufacture, and distribution of proprietary disposable medical devices [5] - The company focuses on interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy [5] - Merit Medical serves hospitals globally with a sales force and clinical support team of over 700 individuals and employs approximately 7,000 people worldwide [5]

SOUTH JORDAN, Utah, May 14, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced US Food and Drug Administration (FDA) 510(k) clearance for its Siege Vascular Plug. Merit also announced the launch of its Bearing nsPVA Express Prefilled Syringe in the United States and Australia. The latest additions to Merit's Embolics portfolio, Siege Vascular Plug and Bearing nsPVA Express, complement a comprehensive offering of microsphere, particle ...

Merit Medical Systems, Inc. (MMSI) delivered adjusted earnings per share (EPS) of 77 cents in the first quarter of 2024 compared with 64 cents in the year-ago period. The figure surpassed the Zacks Consensus Estimate by 8.5%.The adjustments include expenses related to the amortization of intangibles, and Medical Device Regulation expenses, among others.GAAP EPS for the quarter was 48 cents compared with 36 cents in the year-ago period.Revenues in DetailMerit Medical registered revenues of $323.5 million in ...

Merit Medical (MMSI) reported $323.51 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 8.7%. EPS of $0.77 for the same period compares to $0.64 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $315.93 million, representing a surprise of +2.40%. The company delivered an EPS surprise of +8.45%, with the consensus EPS estimate being $0.71.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...

Merit Medical (MMSI) came out with quarterly earnings of $0.77 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.64 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.45%. A quarter ago, it was expected that this maker of disposable medical devices would post earnings of $0.77 per share when it actually produced earnings of $0.81, delivering a surprise of 5.19%.Over the last fou ...